12/13
02:59 pm
rptx
Repare Therapeutics Inc. (NASDAQ: RPTX) had its "market perform" rating re-affirmed by analysts at Lifesci Capital.
Medium
Report
Repare Therapeutics Inc. (NASDAQ: RPTX) had its "market perform" rating re-affirmed by analysts at Lifesci Capital.
12/13
10:34 am
rptx
Repare Therapeutics eyes Phase III cancer study after Mythic trial success [Yahoo! Finance]
High
Report
Repare Therapeutics eyes Phase III cancer study after Mythic trial success [Yahoo! Finance]
12/13
08:31 am
rptx
Repare Therapeutics Inc. (NASDAQ: RPTX) had its price target lowered by analysts at Stifel Nicolaus from $9.00 to $4.00. They now have a "buy" rating on the stock.
High
Report
Repare Therapeutics Inc. (NASDAQ: RPTX) had its price target lowered by analysts at Stifel Nicolaus from $9.00 to $4.00. They now have a "buy" rating on the stock.
12/12
04:20 pm
rptx
Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial
High
Report
Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial
12/10
04:20 pm
rptx
Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial [Yahoo! Finance]
High
Report
Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial [Yahoo! Finance]
12/10
04:05 pm
rptx
Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial
High
Report
Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial
11/12
07:23 am
rptx
Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib [Yahoo! Finance]
Medium
Report
Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib [Yahoo! Finance]
11/12
07:05 am
rptx
Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib
Medium
Report
Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib
11/8
11:37 am
rptx
Repare Therapeutics Inc. (NASDAQ: RPTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Low
Report
Repare Therapeutics Inc. (NASDAQ: RPTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
11/7
07:18 am
rptx
Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results [Yahoo! Finance]
Medium
Report
Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results [Yahoo! Finance]
11/7
07:05 am
rptx
Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results
Low
Report
Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results
10/24
03:27 pm
rptx
Repare Therapeutics Inc. (NASDAQ: RPTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Low
Report
Repare Therapeutics Inc. (NASDAQ: RPTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
10/24
06:15 am
rptx
Repare Therapeutics' individualised anaemia management trial shows promise [Yahoo! Finance]
Low
Report
Repare Therapeutics' individualised anaemia management trial shows promise [Yahoo! Finance]
10/23
06:10 am
rptx
Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial [Yahoo! Finance]
Low
Report
Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial [Yahoo! Finance]
10/23
06:05 am
rptx
Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial
Low
Report
Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial
10/14
05:00 pm
rptx
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Pol? ATPase Inhibitor [Financial Post (Toronto, Ontario, Canada)]
Low
Report
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Pol? ATPase Inhibitor [Financial Post (Toronto, Ontario, Canada)]
10/14
07:11 am
rptx
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Pol? ATPase Inhibitor [Yahoo! Finance]
Medium
Report
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Pol? ATPase Inhibitor [Yahoo! Finance]
10/14
07:05 am
rptx
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Pol? ATPase Inhibitor
Medium
Report
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Pol? ATPase Inhibitor
9/30
04:12 pm
rptx
Repare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination with Radiotherapy Treatment Presented at the ASTRO Annual Meeting [Yahoo! Finance]
High
Report
Repare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination with Radiotherapy Treatment Presented at the ASTRO Annual Meeting [Yahoo! Finance]
9/30
04:05 pm
rptx
Repare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination with Radiotherapy Treatment Presented at the ASTRO Annual Meeting
Low
Report
Repare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination with Radiotherapy Treatment Presented at the ASTRO Annual Meeting
9/27
10:38 am
rptx
Repare Therapeutics Inc. (NASDAQ:RPTX) is definitely on the radar of institutional investors who own 36% of the company [Yahoo! Finance]
Low
Report
Repare Therapeutics Inc. (NASDAQ:RPTX) is definitely on the radar of institutional investors who own 36% of the company [Yahoo! Finance]
9/23
08:17 am
rptx
Repare Therapeutics Inc. (NASDAQ: RPTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Medium
Report
Repare Therapeutics Inc. (NASDAQ: RPTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
9/23
07:12 am
rptx
Repare Therapeutics Announces New Data Underscoring Need for Additional Treatment Solutions for Patients with Metastatic Gynecologic Cancers [Yahoo! Finance]
Medium
Report
Repare Therapeutics Announces New Data Underscoring Need for Additional Treatment Solutions for Patients with Metastatic Gynecologic Cancers [Yahoo! Finance]
9/23
07:05 am
rptx
Repare Therapeutics Announces New Data Underscoring Need for Additional Treatment Solutions for Patients with Metastatic Gynecologic Cancers
Medium
Report
Repare Therapeutics Announces New Data Underscoring Need for Additional Treatment Solutions for Patients with Metastatic Gynecologic Cancers